Back to search

Article

Humoral immune responses remain quantitatively impaired but improve qualitatively in anti-CD20 treated patients with multiple sclerosis after three or four COVID-19 vaccinations

2022-08-11

Abstract excerpt

<h4>Background</h4> Humoral immune responses to COVID-19 vaccination are diminished in anti-CD20 treated patients with multiple sclerosis (pwMS). In healthy individuals, neutralizing antibodies against the SARS-CoV-2 Omicron variant are only detected after three COVID-19 vaccinations. It was hitherto unknown whether a third or fourth COVID-19 vaccination of anti-CD20 treated pwMS improves SARS-CoV-2 specific humor...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
04c12643-9832-5672-afe0-b541aeda1990
DOI
10.1101/2022.08.10.22278639
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Humoral immune responses remain quantitatively impaired but improve qualitatively in anti-CD20 treated patients with multiple sclerosis after three or four COVID-19 vaccinationsDOI 10.1101/2022.08.10.22278639
Preserved T-cell Response in anti-CD20 Treated Multiple Sclerosis Patients Following SARS-CoV-2 VaccinationSemantic proximity
T cell responses to SARS-CoV-2 vaccination in people with multiple sclerosis differ between disease-modifying therapiesSemantic proximity
Response to COVID-19 booster vaccinations in seronegative people with MSSemantic proximity
Immune profiling of COVID-19 vaccine responses in people with multiple sclerosis on B cell-depleting therapySemantic proximity
Effect of different disease-modifying therapies on humoral response to BNT162b2 vaccine in Sardinian multiple sclerosis patientsSemantic proximity
Altered cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapySemantic proximity
Durable T cell immunity to COVID-19 vaccines in MS patients on B cell depletion therapySemantic proximity
Humoral Immune Response Following SARS-CoV-2 mRNA Vaccination and Infection in Pediatric-Onset Multiple SclerosisSemantic proximity
Omicron-specific cytotoxic T-cell responses are boosted following a third dose of mRNA COVID-19 vaccine in anti-CD20-treated multiple sclerosis patientsSemantic proximity
B- and T-cell Specific Responses to Vaccination against SARS-CoV-2 in Anti-CD20 Treated Patients with Relapsing-Remitting or Progressive Form of Multiple Sclerosis Reveal Immunosenescent FeaturesSemantic proximity
Longitudinal follow-up of SARS-CoV-2 vaccine- induced antibody responses in patients with multiple sclerosis treated with anti-CD20 therapySemantic proximity
Patients treated with anti-CD20 therapy can mount robust T cell responses to mRNA-based COVID-19 vaccinesSemantic proximity
Select a neighboring publication to make it the new centre.